Source comparison
Drug Affinity Complex vs CJC-1295 — Same or Different?
A 2009 study published in the Journal of Clinical Endocrinology & Metabolism found that attaching Drug Affinity Complex (DAC) to CJC-1295 extended its half-life from approximately 30 minutes to nearly 8 days. Transforming a peptide that required hourly dosing
This comparison does not assign a generated winner or score.
- A 2009 study published in the Journal of Clinical Endocrinology & Metabolism found that attaching Drug Affinity Complex (DAC) to CJC-1295 extended its half-life from approximately 30 minutes to nearly 8 days. Transforming a peptide that required hourly dosing into one that sustained growth hormone release with a single weekly injection. Our team has guided research teams through hundreds of peptide protocols involving both modified and unmodified CJC-1295. The gap between these two forms comes down to three things most overview guides never clarify: binding mechanism, plasma stability, and dosing frequency implications.
- What is the difference between Drug Affinity Complex and CJC-1295?
- Drug Affinity Complex (DAC) is a synthetic chemical linker covalently bonded to CJC-1295 that extends the peptide's half-life by binding to serum albumin in the bloodstream, preventing rapid enzymatic degradation. Without DAC, native CJC-1295 (also called Modified GRF 1-29) has a half-life of approximately 30 minutes and requires multiple daily administrations to maintain therapeutic growth hormone-releasing hormone (GHRH) receptor activation. The DAC modification transforms CJC-1295 into a long-acting analog with a half-life of 6–8 days, enabling weekly dosing intervals.
- Yes, Drug Affinity Complex fundamentally changes how CJC-1295 behaves in vivo. But calling them 'the same peptide' misses the key distinction. DAC is not an ingredient added to a formulation; it is a covalent modification of the peptide backbone itself. The resulting compound. Often labelled 'CJC-1295 with DAC' or simply 'CJC-1295' in commercial contexts. Has an entirely different pharmacokinetic profile than unmodified CJC-1295 (Modified GRF 1-29, also sold as 'CJC-1295 without DAC'). This article covers exactly how the Drug Affinity Complex modification works at the molecular level, why half-life extension matters for growth hormone secretagogue research, and what preparation and dosing differences researchers must account for when choosing between DAC-modified and non-DAC peptides.